In the second of our ‘In Conversation’ films, Staff Research Scientist Peter Wirnsberger and Senior Research Scientist Daniele Grattarola discuss what inspires them in their work, applying cutting edge ML techniques to drug design. If you’re attending [ICML] Int'l Conference on Machine Learning talk to the team to learn about how these techniques are being applied at Isomorphic Labs. Register your interest here: bit.ly/3VSq6qx #ICML2024
Isomorphic Labs
Biotechnology Research
We are reimagining the entire drug discovery process from first principles with an AI-first approach.
About us
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.
- Website
-
https://www.isomorphiclabs.com/
External link for Isomorphic Labs
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
London, GB
Employees at Isomorphic Labs
Updates
-
We have a range of opportunities to get involved with our work at Isomorphic Labs. If you’re interested in learning more about our interdisciplinary team, catch us at [ICML] Int'l Conference on Machine Learning on 21-27 July and register your interest here: bit.ly/3VSq6qx #ICML2024
-
We’ll be at [ICML] Int'l Conference on Machine Learning 21-27 July - if you’ll be there, we’d love to chat to you about ML for rational drug design and opportunities to join our team. Register here bit.ly/3VSq6qx to arrange a time. #ICML2024
-
As part of #WorkPride 2024, one of our Research Leaders Franca Klingler joins a panel on Empowering Women in STEM Fields, hosted by our partners myGwork - LGBTQ+ Business Community. Sign up here to listen online, June 19th at 2pm BST: bit.ly/3Vvit9y
-
With #AlphaFold 3, an AI model we developed jointly with Google DeepMind, we have an atomic-level view of the structure and interactions of biomolecular systems, deepening our understanding and helping us to reimagine rational drug design. You can find out more in the latest edition of Nature: go.nature.com/4bNNlsJ
-
In the first in a series of ‘In Conversation’ films, we bring together science and tech as Research Scientist Megan Egbert and Machine Learning Engineer Jack L. discuss their work tackling fundamental biological problems at scale by employing machine learning for in silico drug design at Isomorphic Labs. Interested in getting involved? Find our current openings on our website: bit.ly/3wuRQbL #AI #drugdiscovery #machinelearning
-
Our Chief AI Officer, Max Jaderberg, joined the Sana AI Summit a few weeks ago to discuss how AI can help us to reimagine drug design. Catch up with the discussion now if you missed it: bit.ly/45873Nm
Solving deep societal problems with AI is a long-term game. It requires vision, patience, and the ability to translate academic theory into real-world applications. Max Jaderberg and Tuomas Sandholm are shining examples. Max leads the research and application of machine learning for drug discovery at Isomorphic Labs. Last month, Google DeepMind and Isomorphic Labs announced AlphaFold 3, a revolutionary new model that can predict the structure and interactions of all life's molecules with unprecedented accuracy. Tuomas is the architect of Libratus, the first and only AI to beat top human players at Texas hold’em poker. Alongside his research into and application of game theory, Tuomas has focused on medicine. Since 2010, his algorithms have run the USA's national kidney exchange and led to over 10,000 life saving kidney transplants worldwide. Here's a slice of what Max and Tuomas had to say about AI's impact on science and knowledge. Link to the full fireside in comments.
-
+4
-
Our General Counsel Sarah Korman joins a panel discussion with Hans Sauer, Ryan Abbott and Andrei Iancu at #BIO2024. The panel will explore state-of-the-law and policy on AI-generated inventions globally and discuss how biopharma can protect AI inventions and the future of AI-powered innovation.
-
Can we use artificial intelligence to design new drugs? Our Chief Scientific Officer, Miles Congreve, will be delivering the keynote address at Galien Forum UK on May 30th. If you’re attending, join him and learn more about how we’re doing it at Isomorphic Labs. #AI #machinelearning #drugdiscovery
-
Join our CTO Sergei Yakneen at #VivaTech in Paris, May 22nd, 2.40 - 3.15pm CEST as he explores the potential for groundbreaking advancements in healthcare enabled by AI alongside Marion Classe, Alex Devereson, and Julia Hawkins. #AI #machinelearning #drugdiscovery